<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1546-0096-6-S1-P9</ui>
   <ji>1546-0096</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis</p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Salugina</snm>
               <fnm>SO</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Fedorov</snm>
               <fnm>ES</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Alexandrova</snm>
               <fnm>EN</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Novikov</snm>
               <fnm>AA</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Cherkasova</snm>
               <fnm>MV</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Baranov</snm>
               <fnm>AA</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A7">
               <snm>Valogina</snm>
               <fnm>YA</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A8">
               <snm>Nikolaeva</snm>
               <fnm>TN</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A9">
               <snm>Zubova</snm>
               <fnm>NA</fnm>
               <insr iid="I2"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Institute of Rheumatology RAMS, Moscow, Russian Federation</p>
            </ins>
            <ins id="I2">
               <p>Department of Clinical Pathology, Yaroslavl Medical Academy, Yaroslavl, Russian Federation</p>
            </ins>
         </insg>
         <source>Pediatric Rheumatology</source>
         <supplement>
            <title>
               <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p>
            </title>
            <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Micha&#235;l Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor>
            <note>Meeting abstracts &#8211; A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note>
         </supplement>
         <conference>
            <title>
               <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p>
            </title>
            <location>London, UK</location>
            <date-range>14&#8211;17 September 2008</date-range>
            <url>http://www.pres.org.uk</url>
         </conference>
         <issn>1546-0096</issn>
         <pubdate>2008</pubdate>
         <volume>6</volume>
         <issue>Suppl 1</issue>
         <fpage>P9</fpage>
         <url>http://www.ped-rheum.com/content/6/S1/P9</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1546-0096-6-S1-P9</pubid>
         </xrefbib>
      </bibl>
      <history>
         <pub>
            <date>
               <day>15</day>
               <month>9</month>
               <year>2008</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2008</year>
         <collab>Salugina et al; licensee BioMed Central Ltd.</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Objective</p>
         </st>
         <p>To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.</p>
         <p>Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5&#8211;16 years (mean 8.7 &#177; 4.9 years). Systemic JA &#8211; 10 pts (11.8%), poly &#8211; 37 (43.5%), oligo-38 (44.7%). Duration of disease was &lt; 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic &#8211; 2 (20%), poly &#8211; 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA &#8211; 5 (100%), in RF negative pts- 7(17.1%) (p &lt; 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p &lt; 0,001), 14/28 (50%) with UA (p &lt; 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5&#8211;26.4), in RF+ pts (M-834.9; IR 539.3&#8211;1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7&#8211;22.0 U/ml) (p &lt; 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusion</p>
         </st>
         <p>Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.</p>
      </sec>
   </bdy>
</art>
